Kodiak Sciences Inc (KOD)

$4.11 -0.08 (-1.79%)
Market Cap 217.07M
Revenue (ttm) 0.00
Net Income (ttm) -176.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 252,100
Avg Vol 390,566
Day's Range N/A - N/A
Shares Out 52.75M
Stochastic %K 79%
Beta 2.40
Analysts Hold
Price Target $6.80

Latest News on KOD

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 4 weeks ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Mar 10, 2025, 4:39 PM EDT - 6 weeks ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 23, 2025, 8:08 PM EST - 2 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Feb 4, 2025, 7:30 AM EST - 2 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 6:00 AM EST - 3 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Dec 9, 2024, 12:33 PM EST - 4 months ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Kodiak Sciences to Participate in Upcoming Investor Conferences

Nov 11, 2024, 6:15 AM EST - 5 months ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Kodiak Sciences to Present at Innovate Retina 2024

Oct 14, 2024, 5:35 PM EDT - 6 months ago

Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 23, 2024, 6:00 AM EDT - 7 months ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Sep 17, 2024, 4:05 PM EDT - 7 months ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 9 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 29, 2024, 4:36 PM EDT - 11 months ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 21, 2023, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 6, 2023, 5:00 AM EST - 1 year ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Nov 1, 2023, 11:21 PM EDT - 1 year ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Oct 11, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 8, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Sep 7, 2023, 6:00 AM EDT - 1 year ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:38 AM EDT - 1 year ago

Kodiak Sciences scraps development of eye disorder drug

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:36 AM EDT - 1 year ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Jul 24, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences to Present at Upcoming Investor Conferences

May 30, 2023, 4:15 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Mar 28, 2023, 4:08 PM EDT - 2 years ago

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Feb 9, 2023, 7:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Nov 16, 2022, 4:30 PM EST - 2 years ago

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Kodiak: Turnaround Strategy Has Shown Life Thus Far

Nov 14, 2022, 1:17 PM EST - 2 years ago

Kodiak: Turnaround Strategy Has Shown Life Thus Far

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 9, 2022, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

Sep 7, 2022, 4:05 PM EDT - 2 years ago

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Aug 18, 2022, 5:47 PM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 9, 2022, 4:33 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results

Aug 8, 2022, 1:58 PM EDT - 2 years ago

Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

Aug 8, 2022, 6:30 AM EDT - 2 years ago

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Aug 5, 2022, 4:30 PM EDT - 2 years ago

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference

May 27, 2022, 8:00 AM EDT - 3 years ago

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference